Mineralocorticoid Receptor Antagonists for Hypertension Management in Advanced Chronic Kidney Disease

Esaxerenone: First Global Approval

(2019) Sean Duggan   DRUGS

Patiromer versus placebo to enable spironolactone use in patients with resistant hypertension and chronic kidney disease (AMBER): a phase 2, randomised, double-blind, placebo-controlled trial

(2019) Rajiv Agarwal et al.   LANCET

Selective Mineralocorticoid Receptor Cofactor Modulation as Molecular Basis for Finerenone’s Antifibrotic ActivityNovelty and Significance

(2018) Jana Grune et al.   HYPERTENSION

Resistant Hypertension: Detection, Evaluation, and Management: A Scientific Statement From the American Heart Association

(2018) Robert M. Carey et al.   HYPERTENSION

Long-Term Effects of Spironolactone on Kidney Function and Hyperkalemia-Associated Hospitalization in Patients with Chronic Kidney Disease

(2018) Chen-Ta Yang et al.   Journal of Clinical Medicine

2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines

(2017) Paul K. Whelton et al.   HYPERTENSION

Elevated potassium levels in patients with chronic kidney disease: occurrence, risk factors and clinical outcomes—a Danish population-based cohort study

(2017) Reimar W Thomsen et al.   NEPHROLOGY DIALYSIS TRANSPLANTATION

Steroidal and Nonsteroidal Mineralocorticoid Receptor Antagonists Cause Differential Cardiac Gene Expression in Pressure Overload-induced Cardiac Hypertrophy

(2016) Jana Grune et al.   JOURNAL OF CARDIOVASCULAR PHARMACOLOGY

Time-Updated Systolic Blood Pressure and the Progression of Chronic Kidney Disease

(2015) Amanda H. Anderson et al.   ANNALS OF INTERNAL MEDICINE

Effect of Finerenone on Albuminuria in Patients With Diabetic Nephropathy

(2015) George L. Bakris et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Finerenone Impedes Aldosterone-dependent Nuclear Import of the Mineralocorticoid Receptor and Prevents Genomic Recruitment of Steroid Receptor Coactivator-1

(2015) Larbi Amazit et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Spironolactone versus placebo, bisoprolol, and doxazosin to determine the optimal treatment for drug-resistant hypertension (PATHWAY-2): a randomised, double-blind, crossover trial

(2015) Bryan Williams et al.   LANCET

Prediction and Management of Hyperkalemia Across the Spectrum of Chronic Kidney Disease

(2014) Ivana Lazich et al.   SEMINARS IN NEPHROLOGY

Safety and tolerability of the novel non-steroidal mineralocorticoid receptor antagonist BAY 94-8862 in patients with chronic heart failure and mild or moderate chronic kidney disease: a randomized, double-blind trial

(2013) Bertram Pitt et al.   EUROPEAN HEART JOURNAL

Evaluation of cardiovascular disease burden and therapeutic goal attainment in US adults with chronic kidney disease: an analysis of national health and nutritional examination survey data, 2001–2010

(2013) Andreas Kuznik et al.   BMC Nephrology

Blood pressure lowering and major cardiovascular events in people with and without chronic kidney disease: meta-analysis of randomised controlled trials

(2013)   BMJ-British Medical Journal

Rationale and design of ARTS: a randomized, double-blind study of BAY 94-8862 in patients with chronic heart failure and mild or moderate chronic kidney disease

(2012) Bertram Pitt et al.   EUROPEAN JOURNAL OF HEART FAILURE

Intensive Blood-Pressure Control in Hypertensive Chronic Kidney Disease

(2010) Lawrence J. Appel et al.   NEW ENGLAND JOURNAL OF MEDICINE

Hypertension Awareness, Treatment, and Control in Adults With CKD: Results From the Chronic Renal Insufficiency Cohort (CRIC) Study

(2009) Paul Muntner et al.   AMERICAN JOURNAL OF KIDNEY DISEASES